Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in MAPK Pathway Mutant CNS Tumors
NCT07539441Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in central nervous system tumor, glioma, histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
central nervous system tumorgliomahistiocytosis
Beyond the preview
Go deeper on NCT07539441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539441.